BL-B01D1
Based on 1 Customer Validation
BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- Antibody:
- Linker-Payload:
-
Drug-to-Antibody Ratio:
8
-
Conjugate Type:
Random Cysteines
- 純度 : 98.59%
- CAS 番号: 2760528-47-8
- 分子量:205830.00
-
保管条件:Shipping with dry ice
-80°C, protect from light
生物活性
製品説明
|
Topoisomerase I |
EGFR |
HER3 |
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- PCNA Immunodetection Proliferation Assay
- Flow cytometric DNA-content cell-cycle staining
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Cell Viability Determination by MTT Colorimetric Assay
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Product Details
-
Antibody
-
Linker-Payload
-
Drug-to-Antibody Ratio
8
-
Conjugate Type
Random Cysteines
化学情報
-
CAS 番号 2760528-47-8
-
性状 Liquid
-
分子量 205830.00
-
Color Colorless to light yellow
-
SMILES
[BL-B01D1]
-
別名
Izalontamab Brengitecan; BMS 986507
-
輸送条件
Shipping with dry ice.
-
保管条件
-80°C, protect from light
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- BL-B01D1
- 2760528-47-8
- Izalontamab Brengitecan
- BMS 986507
- BMS986507
- BMS 986507
- BMS-986507
- Antibody-Drug Conjugates (ADCs)
- EGFR
- Topoisomerase
- Antibody-Drug Conjugates
- ADC
- Epidermal growth factor receptor
- ErbB-1
- HER1
- HER3
- urothelial carcinoma
- camptothecin derivative
- pancreatic cancer
- xenograft models
- metastatic esophageal squamous cell carcinoma
- colorectal cancer
- topoisomerase I
- non-small cell lung cancer
- Inhibitor
- inhibitor
- inhibit